Skip to content

IAS: TMC114 plus low-dose ritonavir effective and well-tolerated in 3-class-experienced HIV patients

IAS: New tablet formulation of Kaletra is on its way, manufacturer says

IAS: ‘Next generation’ NNRTI GW695634 is safe and active in NNRTI-resistant patients

IAS: New NRTI D-d4FC active in treatment-experienced patients

IAS: Growth hormone improves CD4 cell count in patients with a poor response to HAART

IL-2 increases CD4 cell counts by prolonging CD4 T-cell survival

Methadone included, tenofovir excluded, from new WHO essential drugs list

Pegylated interferon superior to lamivudine for first line hepatitis B treatment

Pfizer discontinues capravirine development